OTCM
EMITF
Market cap21mUSD
Sep 28, Last price
0.05USD
Name
Elbit Imaging Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Elbit Imaging Ltd. is an Israeli-based company, with operations extending internationally, that specializes in the creation, production, and distribution of therapeutic medical systems designed for non-invasive procedures on the human body. Their offerings include advanced medical devices that leverage ultrasound beam technology and magnetic resonance imaging for treatment purposes. Furthermore, the company develops medical solutions utilizing stem cells, primarily derived from umbilical cord blood. These stem cell products are intended for bone marrow transplantation in patients suffering from conditions such as leukemia, lymph node cancer, various non-malignant blood disorders, and inherited metabolic diseases. Beyond its medical ventures, Elbit Imaging also holds real estate interests, specifically in the sale of land parcels and villas within India. The company, founded in 1996, changed its name from Elbit Medical Imaging Ltd. to its current designation in November 2007, and it is headquartered in Petach Tikva, Israel.
Key people
Chief Financial Officer · since 2016
Zvi Maayan
Vice President, General Counsel · since 2008
Oren Kolton
India Country Director · since 2010
Chairman of the Board
Moshe Lion
Director · since 2006
Shmuel Peretz
Director · since 2006
Director · since 2003
Hanoch Ehrlich
External Director · since 2019
Shlomo Nissim
External Director · since 2019
External Independent Director · since 2008
Zvi Tropp
External and Independent Director · since 2004
Headquarters & legal address
5 KINNERET STREET
BNEI BRAK, TA 51261
IL
BNEI BRAK, TA 51261
IL
Valuation
Title ILS in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||